What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Today, 8:19 AM
- CVS Health (CVS -3.7%) Q4 results: Revenues: $41,145M (+11.0%); Operating Expense: $4,572M (+6.0%); Operating Income: $2,729M (+17.6%); Net Income: $1,499M (+13.4%); EPS: $1.34 (+17.5%); Non-GAAP EPS: $1.53 (+26.4%).
- FY2015 results: Revenues: $153,290M (+10.0%); Operating Expense: $17,074M (+3.1%); Operating Income: $9,454M (+7.4%); Net Income: $5,228M (+12.6%); EPS: $4.62 (+16.7%); Non-GAAP EPS: $5.16 (+14.9%); Quick Assets: $2,547M (+1.3%).
- Q1 Guidance: GAAP EPS: $1.03 - 1.06; Adjusted EPS: $1.14 - 1.17.
- 2016 Guidance: GAAP EPS: $5.28 - 5.43; Adjusted EPS: $5.73 - 5.88; CF Ops: $7.6B - 7.9B.
Today, 6:52 AM
Yesterday, 5:30 PM
Fri, Jan. 29, 12:03 PM
- Medifast (MED +1.4%) initiated with Hold rating and $32 (10% upside) price target by Wunderlich.
- Kite Pharma (KITE +4.1%) initiated with Buy rating and $70 (51% upside) price target by SunTrust Robinson Humphrey.
- STAAR Surgical (STAA +0.3%) initiated with Hold rating by Benchmark.
- Nektar Therapeutics (NKTR -2.4%) initiated with Buy rating and $21 (57% upside) price target by Janney Capital.
- BioBlast Pharma (ORPN +7.7%) initiated with Buy rating and $25 (574% upside) price target by H.C. Wainwright.
- CVS Health (CVS +1.3%) initiated with Outperform rating and $108 (14% upside) price target by Baird.
- Walgreens Boots Alliance (WBA +1.1%) initiated with Outperform rating and $96 (22% upside) price target by Baird.
- Intercept Pharma (ICPT +0.6%) upgraded to Equal Weight from Underweight by Morgan Stanley. Price target is $100 (0% upside).
- Stryker (SYK +1.8%) upgraded to Buy from Hold by Brean Capital. Price target is $115 (16% upside).
- Voyager Therapeutics (VYGR -0.7%) upgraded to Neutral from Sell by Chardan Capital. Price target lowered to $15 (50% upside) from $20.
- Bristol-Myers Squibb (BMY +1.9%) upgraded to Buy from Hold by Berenberg. Price target raised to $77 (24% upside) from $74.
- Oncomed Pharmaceuticals (OMED -0.3%) downgraded to Market Perform from Outperform by Leerink. Price target lowered to $11 (23% upside) from $27.
- Regeneron Pharmaceuticals (REGN +0.6%) downgraded to Sell from Neutral by Chardan Capital. Price target lowered to $400 (4% downside risk) from $525.
Wed, Jan. 13, 8:28 AM
- According to Bloomberg, heath insurer Anthem (NYSE:ANTM) is aiming to get an additional $3B per year in drug discounts from pharmacy benefits manager (PBM) Express Scripts (NASDAQ:ESRX) and, if it doesn't get it, is threatening to take its business elsewhere.
- Anthem CEO Joseph Swedish commented on the tussle yesterday at the J.P. Morgan Healthcare Conference in San Francisco. "We are entitled to improved pharmaceutical pricing that equates to an annual value capture of more than $3B. To be clear, this is the amount by which we would be overpaying for pharmaceuticals on an annual basis. Much of those savings would be passed on to clients."
- Anthem has an unusual relationship with Express under which it is entitled to periodic reviews of the prices it pays for drugs, the last of which occurred in 2012. The arrangement stems from Anthem's sale of its PBM business to Express in 2009.
- Express spokesman Brian Henry says that Anthem is mischaracterizing the situation, adding, "Express Scripts has consistently acted in good faith and is in full compliance with the terms of its agreement. While the contract calls for good faith negotiations regarding a pricing review, it does not mandate specific price adjustments. Furthermore, Anthem is not entitled to $3B."
- Negotiations are ongoing. If Anthem makes good on its threat, it only has two choices of PBMs, CVS Health (NYSE:CVS) and UnitedHealth Group's (NYSE:UNH) OptumRx. According to Evercore ISI's Ross Muken, Anthem's exit would shave $0.80 per share off ESRX's earnings.
- ESRX is down 5% premarket on light volume.
Dec. 18, 2015, 12:18 PM
- Biogen (BIIB +0.2%) initiated with Overweight rating and $344 (16% upside) price target by Atlantic Equities.
- CVS Health (CVS -0.1%) initiated with Overweight rating and $110 (16% upside) price target by Barclays.
- Clovis Oncology (CLVS +0.9%) initiated with Buy rating and $50 (48% upside) price target by Janney.
- Relypsa (RLYP +2.6%) initiated with Buy rating and $63 (123% upside) price target by H.C. Wainwright.
- HCA Holdings (HCA -0.2%) initiated with Outperform rating and $75 (16% upside) price target; LifePoint Health (LPNT +0.4%) with an Outperform rating and $79 (13% upside) price target; Tenet Healthcare (THC +1.2%) with a Neutral rating and $33 (18% upside) price target and Universal Health Services (UHS +0.4%) with a Neutral rating and $129 (11% upside) price target by Credit Suisse.
- Amgen (AMGN -0.1%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $193 (20% upside) from $160.
- Valeant Pharmaceuticals (VRX -1.8%) downgraded to Neutral from Buy by Mizuho Securities. Price target raised to $130 (19% upside) from $111.
Dec. 16, 2015, 8:12 AM
- The $1.9B deal has CVS Health (NYSE:CVS) adding Target's (NYSE:TGT) 1,672 pharmacies across 47 states, and CVS will operate them through a store-within-a-store format, branded as CVS/pharmacy. In addition, this brand will be included in all new Targets offering pharmacy services, and 79 Target clinic locations will be rebranded as MinuteClinic.
- Target will recognize a pretax gain of $575M-$775M in Q4 (though will be excluded from adjusted EPS). Q4 revenues will be cut by about $500M.
- The sale isn't expected to change Q4 comp sales.
- After-tax net proceeds will be about $1.2B, which will be deployed over time into capital priorities, including buybacks. The deal is expected to be accretive to EBITDA and EBIT margin rates, and had 50 basis points or more to return on invested capital over time.
- This deal and more will be discussed at CVS' investor day today.
- Source: Press release
- TGT +0.9%, CVS +2.05% premarket.
- See also: CVS raises its outlook and boosts the dividend.
Dec. 16, 2015, 7:44 AM
Dec. 1, 2015, 12:53 PM
- In a shining example of the beauty of competition, Amgen (AMGN +0.5%) is battling fiercely with Sanofi (SNY) and Regeneron (REGN -0.4%) for favored status of its cholesterol fighter Repatha (evolocumab) versus Praluent (alirocumab) in the leading pharmacy benefit managers (PBMs).
- Amgen won preferred listing in CVS Health (CVS +1.4%) and an exclusive deal with Harvard Pilgrim Health System. Express Scripts (ESRX +1.2%) covers both PCSK9 inhibitors while UnitedHealth's (UNH +2.5%) Oxford unit is taking a different approach. Plan members will have to try Praluent first. If it fails to do the job after 12 weeks, then they can try Repatha.
- UnitedHealth and its OptumRx PBM are largest unsigned accounts and are, no doubt, getting substantial exposure to the companies' representatives.
Nov. 23, 2015, 9:18 AM
- Round one in the Repatha (evolocumab) versus Praluent (alirocumab) competition goes to Amgen (NASDAQ:AMGN). After evaluating both PCSK9 inhibitors, Pharmacy benefit manager CVS Health (NYSE:CVS) exclusively adds Amgen's Repatha to its commercial formularies, effectively shutting out Sanofi (NYSE:SNY) and Regeneron's (NASDAQ:REGN) Praluent.
- No word yet on the decisions from other PBMs.
Oct. 30, 2015, 10:16 AM
- CVS Health (CVS -6.3%) Q3 results: Revenues: $38,644M (+10.3%); COGS: $31,983M (+12.0%); Operating Expense: $4,330M (+2.6%); Operating Income: $2,331M (+3.8%); Net Income: $1,236M (+30.4%); EPS: $1.10 (+35.8%); Quick Assets: $3,011M (+19.7%); CF Ops: $4,841M (+2.7%).
- Q4 Guidance: $1.51 - 1.55; GAAP EPS: $1.41 - 1.45.
- 2015 Guidance: Adjusted EPS: $5.14 - 5.18; GAAP EPS: $4.69 - 4.73; CF Ops: $7.6B - 7.9B; FCF: $5.9B - 6.2B.
- 2016 Preliminary Outlook: Preliminary Adjusted EPS: $5.68 - 5.88.
Oct. 30, 2015, 6:53 AM
- CVS Health (NYSE:CVS): Q3 EPS of $1.29 in-line.
- Revenue of $38.64B (+10.3% Y/Y) beats by $750M.
Oct. 29, 2015, 5:30 PM| Oct. 29, 2015, 5:30 PM | 19 Comments
Oct. 29, 2015, 3:54 PM
- According to CNBC, CVS Health (CVS +0.3%) has kicked Philidor Rx out of its network for some sort of "noncompliance" with its provider agreement. Option holder Valeant Pharmaceuticals (VRX -4.6%) is down on the news.
- Previously: Notes from Valeant's conference call (Oct. 26)
- Previously: Valeant confirms appropriateness of accounting (Oct. 26)
Oct. 29, 2015, 2:32 AM
- Top antitrust lawmakers in the U.S. Senate are calling for close scrutiny of Walgreens Boots Alliance's (NASDAQ:WBA) plan to buy Rite Aid (NYSE:RAD), the latest healthcare consolidation following the rollout of the Affordable Care Act.
- The deal would unite two of the three largest U.S. drugstore chains, the other being CVS Health (NYSE:CVS).
- Walgreens Chief Executive Stefano Pessina said previously that the company had analyzed the antitrust aspect of the deal but did not speculate on the number of drugstores it might need to divest in order to win regulatory approval.
- Previously: Walgreens buying Rite Aid for $17.2B ($9/share) (Oct. 27 2015)
Oct. 5, 2015, 12:44 PM
- Blame it (mostly) on energy/commodities as Markit expects another 62% cut in dividends in the basic resources sector. Payouts in the media sector will decline 21%, but this is due to Disney switching from paying annually to semi-annually, and reallocating $1.1B in returns to next year.
- In total, Markit sees dividend growth of just 3.4% in Q4, down from 11.5%, 11.4%, and 24.1% growth in the previous three quarters. Special dividends in Q4 this year will total just $1.5B, down from $5.6B a year ago.
- The top five dividend increases coming in Q4: MasterCard (NYSE:MA) is expected to boost its payout by 31%; Visa (NYSE:V) by 25%, CVS (NYSE:CVS) Health by 23%, Lincoln Financial (NYSE:LNC) by 20%, and Starbucks (NASDAQ:SBUX) by 19%.
- ETFs: DVY, SCHD, ADX, SDOG, DLN, DHS, FDL, DTD, FVD, DVYL, SDYL
Other News & PR